Mycobacterium tuberculosis Dihydrofolate Reductase Reveals Two Conformational States and a Possible Low Affinity Mechanism to Antifolate Drugs  by Dias, Marcio Vinicius Bertacine et al.
Structure
ArticleMycobacterium tuberculosis Dihydrofolate Reductase
Reveals Two Conformational States and a Possible
Low Affinity Mechanism to Antifolate Drugs
Marcio Vinicius Bertacine Dias,1,2,* Petros Tyrakis,1 Romenia Ramos Domingues,2 Adriana Franco Paes Leme,2
and Tom L. Blundell1
1Department of Biochemistry, University of Cambridge, Tennis Court Road, Cambridge CB2 1QA, UK
2Laborato´rio Nacional de Biocieˆncias (LNBio), Centro de Nacional de Pesquisa em Energia e Materiais, Campinas, (CNPEM),
Sa˜o Paulo 13083-100, Brazil
*Correspondence: bertacine@gmail.com
http://dx.doi.org/10.1016/j.str.2013.09.022SUMMARY
Inhibition of the biosynthesis of tetrahydrofolate
(THF) has long been a focus in the treatment of
both cancer and infectious diseases. Dihydrofolate
reductase (DHFR), which catalyzes the last step, is
one of the most thoroughly explored targets of this
pathway, but there are no DHFR inhibitors used for
tuberculosis treatment. Here, we report a structural,
site-directed mutagenesis and calorimetric analysis
of Mycobacterium tuberculosis DHFR (MtDHFR) in
complex with classical DHFR inhibitors. Our study
provides insights into the weak inhibition of MtDHFR
by trimethoprim and other antifolate drugs, such as
pyrimethamine and cycloguanil. The construction of
themutant Y100F, together with calorimetric studies,
gives insights into low affinity of MtDHFR for clas-
sical DHFR inhibitors. Finally, the structures of
MtDHFR in complex with pyrimethamine and cyclo-
guanil define important interactions in the active
site and provide clues to the more effective design
of antibiotics targeted against MtDHFR.
INTRODUCTION
Tetrahydrofolate (THF) is an essential coenzyme that acts as a
carrier for one-carbon (C1) units in the biosynthesis of thymidy-
late, purine nucleotides, and some amino acids, such as serine,
methionine, and glycine in both prokaryotic and eukaryotic or-
ganisms (Hanson and Gregory, 2011). It is essential for DNA,
RNA, and protein biosynthesis, especially in fast growing cells.
Thus, several of the enzymes involved in its biosynthesis have
been explored as targets in cancer and transplant therapies
(Schweitzer et al., 1990).
THF is synthesized from three moieties: pterin, p-aminoben-
zoate (pABA), and glutamate (Figure 1A). In bacteria and plants,
the pterin moiety is produced by the conversion of guanosine
triphosphate (GTP) to 6-hydroxymethyl-7,8-dihydropterin
pyrophosphate (DHPPP) in four enzymatic steps, and pABA is
derived from chorismate using the enzymes aminodeoxychoris-94 Structure 22, 94–103, January 7, 2014 ª2014 Elsevier Ltd All rightmate synthase and aminodeoxychorismate lyase (Dosselaere
and Vanderleyden, 2001). The condensation of pterin and
pABA, catalyzed by dihydropteroate synthase, is followed
by the addition of glutamate by folylpolyglutamate synthase
to give 7,8-dihydrofolate. The final step in the synthesis of THF
(Figure 1B) (Bermingham and Derrick, 2002) is the NADPH-
dependent reduction of dihydrofolate to tetrahydrofolate by
dihydrofolate reductase (DHFR).
DHFR is one of the most widely targeted enzymes in human
therapy medicine (Schweitzer et al., 1990; Bermingham and
Derrick, 2002). Its inhibition by methotrexate and aminopterin
has been extensively used in cancer, immunosuppressive, and
anti-inflammatory therapy. Aminopterin was one of the first
effective drugs against acute lymphocytic leukemia in children
and methotrexate was one of the first for solid tumors (Bertino,
2009; Huennekens, 1994, Kisliuk, 2003). Selective DHFR inhibi-
tors, such as trimethoprim and pyrimethamine (Figure 1C), are
important in the treatment of bacterial and protozoal infections
respectively; they are potent inhibitors of DHFR from microor-
ganisms but weakly inhibit human DHFR (Kompis et al., 2005;
Hawser et al., 2006).
Tuberculosis is an important public health problem in many
parts of the world. It is estimated that one-third of world popula-
tion is infected with Mycobacterium tuberculosis, which causes
the death of more than one million people each year (WHO,
2012). Although trimethoprim and other DHFR inhibitors have
important roles in combating several infections, they are not
used in the treatment of tuberculosis because they have little
or no activity against the growth of M. tuberculosis (Vilche`ze
and Jacobs, 2012). However, the determination of the structure
of DHFR from M. tuberculosis (MtDHFR) has opened up oppor-
tunities for the development of new drugs against this target.
Comparison of the human and M. tuberculosis enzymes has
revealed key differences that can be exploited in structure-
guided drug discovery (Li et al., 2000). The structures of MtDHFR
in complex with trimethoprim and WR99210, a potential antima-
larial drug, have been obtained (Li et al., 2000), revealing key
interactions between these flexible inhibitors and the enzyme.
Furthermore, several groups have focused on obtaining potent
inhibitors and pharmacologically active molecules against
MtDHFR by carrying out structure-based analyses (Kumar
et al., 2010, 2012; El-Hamamsy et al., 2007; Gerum et al.,
2002). However, structural studies with rigid inhibitors such ass reserved
Figure 1. Chemical Structures of Dihydrofo-
late and Antifolate Drugs and the Steps of
Tetrahydrofolate Biosynthesis
(A) Moieties of tetrahydrofolate.
(B) Biosynthetic pathway of tetrahydrofolate from
chorismate and GTP.
(C) Clinical antifolate drugs that are potent
inhibitors of bacterial and protozoal DHFRs.
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Mycobacterium Tuberculosis DHFR Structurespyrimethamine and cycloguanil, which are potent antimalarial
compounds, have not been reported and the flexibility and
dynamics of the domains and loops of MtDHFR during the cata-
lytic cycle are not understood.
Here, we report the structure of MtDHFR in a ternary complex
with NADPH and three different classic inhibitors of DHFR of
microorganisms: trimethoprim, pyrimethamine, and cycloguanil
(Figure 1C). We have identified a conformational state that af-
fects the binding of the ribose-nicotinamide moieties of NADPHStructure 22, 94–103, January 7, 201and leads to trimethoprim binding in
a completely different mode. We also
show the structures in complex with pyri-
methamine and cycloguanil that provide
insights that should assist the design
and development of new candidate drugs
for tuberculosis.
RESULTS AND DISCUSSION
We have solved the structures of ternary
complexes of MtDHFR with NADPH
and with three classical inhibitors of
DHFR: trimethoprim (TMP), pyrimeth-
amine (PYR), and cycloguanil (CYC). The
crystals of the binary complex with
NADPH gave the highest resolution
(1.23 A˚) structure for this enzyme so far
(Table 1). All the ternary complexes have
been crystallized in conditions and space
groups that differ from those reported
in the literature and giving resolutions
between 1.30 and 2.3 A˚ (Table 1).
The structures of MtDHFR in these
complexes exhibit the overall fold first
described by Li et al. (2000), consisting
of a central b sheet with six parallel
strands and four flanking a helices
(Matthews et al., 1977) (Figure 2). How-
ever, only one of the structures, the
MtDHFR:NADPH binary complex, super-
poses well with the structures solved
by Li et al. (2000) (root-mean-square de-
viation [rmsd] = 0.63 A˚), although even
here there are small movements in the
region of the dihydrofolate binding site
(figure not shown). The other structures,
which have no density for the ribose-
nicotinamide moiety of NADPH, do not
superpose well with structures solvedpreviously (rmsd = 1.05 A˚); we denominate them as having an
‘‘open’’ conformation, in contrast to the structure described by
Li et al. (2000) that has a ‘‘closed’’ conformation.
The two conformations, corresponding to open and closed
states, observed in the structures of MtDHFR (Figure 3), have
not previously been observed for the M. tuberculosis enzyme.
The closed structure of the binary MtDHFR:NADPH complex
was crystallized in space group C2 and has one molecule in
the asymmetric unit. On the other hand, the structures in the4 ª2014 Elsevier Ltd All rights reserved 95
Table 1. CrystallizationConditions, Data Collection, andCrystallography Statistics of theMtDHFR inComplexwith Different Inhibitors
or Different Conformational States
Open MtDHFR:
NADPH
Closed MtDHFR:
NADPH
MtDHFR:NADPH:
TMP
MtDHFR:NADPH:
Pyr
MtDHFR:NADPH:
Cyc
PDB ID 4KLX 4KL9 4KM2 4KM0 4KNE
Crystallization
conditions
8% PEG 4000
at 20C
0.1 M MES, pH 6.5,
25% PEG 2000
MME at 20C
0.1 M sodium acetate,
pH 4.6, 8% PEG 4000
at 20C
0.05 M KCl, 0.01 M
MgCl2, 15% PEG
6000 at 20C
8% PEG 4000 (soaking
of cycloguanil) at 20C
Cryoprotector 25% PEG 2000 MME None 25% PEG 2000 MME 25% PEG 2000 MME 25% PEG 2000 MME
X-Ray Diffraction Data and Refinement
Beamline ESRF ID14-1 SLS X06DA SLS X06DA SLS X06DA SLS X06DA
Wavelength (A˚) 0.93 0.97 1.0 1.0 1.0
Resolution 76.77–1.23 49.46–1.39 50.51–1.4 76.74–1.3 76.89–2.0
Space group P21 C2 P212121 P21 P21
Unit cell (A˚)
a, b, c 32.41, 63.06, 78.16 67.58, 76.59, 36.83 64.16, 65.28, 79.75 32.32, 63.45, 78.12 33.0, 63.9, 78.30
a, b, g () 90.0, 100.82, 90.0 90.0, 98.77, 90.0 90.0, 90.0, 90.0 90.00, 100.8, 90.00 90.00, 100.788, 90.00
Resolution range (A˚) 19.87–1.23 23.03–1.39 20.99–1.4 17.98–1.3 32.94–2.0
Highest resolution
shell (A˚)
1.3–1.23 1.46–1.39 1.48–1.40 1.37–1.30 2.11–2.0
Rsym(%)
a 10.7 (47.4) 3.8 (58.6) 10.4 (77.1) 7.3 (41.3) 0.169 (33.7)
Completeness (%) 99.3 (97.9) 99.9 (100) 99.0 (98.0) 99.4 (98.4) 96.9(97.4)
Unique reflections (n) 88,928 (12,800) 36,064 (5,250) 65,906 (9,385) 75,734 (10,884) 20,838 (3,046)
Multiplicity 3.3 (3.2) 3.8 (3.7) 8.9 (8.8) 4.4 (4.2) 3.9 (3.8)
Average intensity, hI/s(I)i 7.0 (2.4) 15.3 (2.2) 13.5 (3.0) 11.5 (3.4) 6.3 (3.3)
Subunits in the a.u. 2 1 2 2 2
Rmsd of the subunits
in the a.u.
0.3 — 0.6 0.4 0.3
Rcryst
b 18.3 15.5 14.0 15.5 20.7
Rfree
c 24.4 20.2 20.1 21.0 26.9
Nonhydrogen atoms (n) 3,096 1,497 3,205 3,067 3,023
Water molecules (n) 523 178 613 463 430
Factor Analysis (A˚2)
Main chain 7.97 22.39 11.09 9.88 12.66
Side chain 11.91 27.55 15.47 13.45 14.7
Waters 25.67 40.99 30.74 26.76 20.10
NADP(H) 8.88 19,19 11.38 10.83 13.96
DHFR inhibitor — — 8.00 6.81 10.24
Model Quality
Ramachandran plot
analysisd (%)
Most favored 92.0 94.7 93.5 93.9 92.7
Additional allowed 7.2 5.3 6.5 5.7 7.3
Generously allowed 0.4 0 0 0 0
Disallowed 0.4 0 0 0.4 0
Rmsd of ideal
geometry
Bond (A˚) 0.025 0.024 0.024 0.024 0.008
Angle () 2.48 2.39 2.43 2.33 1.342
a.u., arbitrary units; DHFR, dihydrofolate reductase; rmsd, root-mean-square deviation. Values in parentheses refer to the highest resolution shell.
aRsym = ShrIh hIir/ShIh, where Ihis the intensity of reflection h hIi is the mean intensity of all symmetry-related reflections.
bRfactor = SjjFobsj  jFcaljj/SjFobsr, where Fcalc and Fobs are observed and calculated structure factor amplitudes.
cRfree = Rfactor, but using a random subset of the data (5%) that is excluded from the refinement.
dThe stereochemical analysis was obtained by Procheck (Laskowski et al., 1993).
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Figure 2. Structure of MtDHFR with the Elements of Secondary
Structure Labeled
The organization into two domains established earlier for EcDHFR (Sawaya
and Kraut, 1997) is evident.
Figure 3. Superposition of the Open and Closed Forms of MtDHFR
Showing the Displacement of the Adenosine Domain
Superposition of secondary elements of the open (orange) and closed (green)
forms of MtDHFR. The superposition was carried out by fixing the Loop
domain and then the rmsd for the displacement of the adenosine domain was
obtained (1.6 A˚). The rotation angle of the adenosine domain (9.3) was
calculated taking as the origin at Ala126 CA (black arrow in the figure) on the L4
and the end points at Asp38 CA on the helix aC in both structures. The dis-
tances of the relative displacement are also shown for the L2, aC, aF, and
NADPH. Structure of MtDHFR in open conformation shows a truncated
NADPH. To prove that NAPDH is not degraded in our structures we performed
extensive mass spectra analyses as could be observed in the Figure S1.
Structure
Mycobacterium Tuberculosis DHFR Structuresopen state, which include a further structure of the binary com-
plex with NADPH as well as the ternary complexes with inhibi-
tors, were crystallized in the space groups P21 or P212121 and
have two molecules in the asymmetric unit (Table 1). The rmsd
of the two subunits in the asymmetric unit is 0.3–0.6 A˚ and
the values are also summarized in the Table 1.
Thus, all structures that we have solved in complex with inhib-
itors have the open state where density for the nicotinamide-
ribose moiety of the NADPH could not be observed (Figure 3).
This moiety may be disordered in the absence of the substrate
dihydrofolate. We considered it unlikely that NADPH was
degraded in the presence of the phosphate buffer or because
of the acidity of the crystallization conditions, because we have
used the same buffers as described by Li et al. (2000) and
Argyrou et al. (2006) and most of the crystals appeared at pH
4.6, as reported previously by these authors. Nevertheless, we
tested this for both theMtDHFR:NADPH complex and NADPH it-
self by mass spectroscopy (Figure S1 available online). In all sets
of experiments with different concentrations of ligands in the
conditions where the best crystals were obtained, with excep-
tion of absence of polyethylene glycol, no mass of for a NADPH
missing the nicotinamide group has been identified (Figure S1).
Movements of Subdomains and Loops in MtDHFR
The enzymatic mechanism of MtDHFR has been described by
Czekster et al. (2011a, 2011b) but conformational changes of
the enzyme during the catalytic cycle have not been reported
forM. tuberculosis. The flexibility of the nicotinamide-ribosemoi-
ety in our structures reveals key movements that could be
involved in its catalytic cycle. The dynamics of loops and do-
mains in the DHFR mechanism have been extensively studied
in Escherichia coli (EcDHFR) (Sawaya and Kraut, 1997, Schnell
et al., 2004). Based on the structure of EcDHFR, Bystroff and
Kraut (1991) and Sawaya and Kraut (1997) describe the enzyme
as having two domains, the Adenosine and the Loop domains.
Three principal loops of the enzyme (the M20, F-G, and G-H,Structure 22,which in MtDHFR we call L1, L4, and L5, respectively) are
located in the Loop domain (Figures 2 and 4B). Bystroff and
Kraut (1991) classified the conformational states of the EcDHFR
enzyme as open, closed, occluded, and disordered, mainly
based on the movements of the loop M20 (Figure 4B).
The closed state of MtDHFR, as we would expect, is better
superposed with the closed state of EcDHFR than the occluded
and the open states (Figure 4) and the L1 and L4 loops of
MtDHFR adopt similar positions to those of the M20 and F-G
loops of EcDHFR, respectively. However, the L5 loop does not
superpose with the G-H loop of EcDHFR in any state, probably
due to differences in the sequences.
On the other hand, the open state of the MtDHFR does not
superpose well with any state of EcDHFR and probably different
movements occur during the binding of the substrate and
cofactor. The L1 (that corresponds to the M20 loop in EcDHFR),
the L2 loop, which is not described in EcDHFR and is a small and
rigid region of the Adenosine domain, and the aC helix are more
separated thanM20 and the corresponding regions of L2 and aC
in EcDHFR. The conformations of these three regions give rise to
a large cavity that accommodates dihydrofolate in MtDHFR.
Similar differences are also observed in a comparison of the
open and closed states of MtDHFR.
Therefore, probably the engagement of the nicotinamide
group in the active site or the binding of dihydrofolate triggers
conformational changes in MtDHFR that allow movements of
L1, L2, and aC to close over the active site (Figure 3) and hold94–103, January 7, 2014 ª2014 Elsevier Ltd All rights reserved 97
Figure 4. Superposition of the Ca Atoms of Different Conformational States of EcDHFR and MtDHFR
The identity of the two sequences is 33.9%.
(A) Secondary structural elements, names and positions of the loops in EcDHFR. The names of the loops in MtDHFR are L1, L4, and L5 for Met20, and F-G and
G-H in EcDHFR, respectively.
(B) Superposition of the open state of MtDHFR (blue) and the three different states of EcDHFR, open (green), closed (yellow), and occluded (red).
C) Superposition of the open state of MtDHFR (blue) and the closed state of EcDHFR (yellow).
(D) Superposition of the closed state of MtDHFR (blue) and closed state of EcDHFR (yellow).
(E) Superposition of the closed (green) and open (red) state of MtDHFR.
(F) Superposition of the MtDHFR in ternary complex with NADPH and MTX (orange) and binary complex with NADPH in closed state (blue).
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Mycobacterium Tuberculosis DHFR Structuresdihydrofolate in the catalytic position. As a consequence, the
NADPH also reorients, moving 1.7 A˚ toward the active site,
placing the nicotinamide group in a position to make a p-p
face-edge interaction with the pterin group of dihydrofolate
(Figure 3B).
Supporting the importance of flexibility of the nicotinamide
group of NADPH in the active site of MtDHFR, Schnell et al.
(2004) has described a concerted and cooperative mechanism
between the cofactor NADPH and its substrate for DHFR from
Lactobacillus casei. This is in agreement with the conformational
changes observed in our structures, which may influence the
binding of dihydrofolate and the ordering of ribose-nicotinamide
moiety (Schnell et al., 2004). L. casei DHFR has been extensively
studied in the presence of NADP+ by NMR and two different
conformational states that differ in the position of the NADP+
have been found. In the first form, the NADP+ is buried in the pro-
tein and in the second the nicotinamide group is out of the active
site, influencing the position of the ribose and pyrophosphate of
NADP+ (Birdsall et al., 1984), in a similar way to that observed in
our structures. MtDHFR and LcDHFR have an identity of 30%
and therefore LcDHFRcould be used in our comparative analysis.
The Binding of TMP in the Open State of MtDHFR
TMP binds in the same pocket in both open and closed states of
MtDHFR, but in completely different modes. Consequently, reor-98 Structure 22, 94–103, January 7, 2014 ª2014 Elsevier Ltd All rightientations of the side chains of Phe31, Leu50, and Ile120 are
observed. As a result, the pyrimidine ring of TMP is shifted by
1.7 A˚ toward theNADPHbinding site in the open-state structure
and the two degrees of conformational freedom (q1 and q2) in
TMP (Figure 5C) allow the trimethoxybenzyl group to adopt a
new position perpendicular to Phe31. There is an angle of 15
between the planes of the pyrimidine rings in the two struc-
tures, leading to a difference of direction of the vector of C7 (Fig-
ure 5D). Therefore, the trimethoxybenzyl group in our open
MtDHFR:NADPH:TMP structure is almost perpendicular to that
in the MtDHFR:NADPH:TMP structure solved by Li et al. (2000).
Thus, we believe that the reorientation of TMP may be caused
by absence of the nicotinamide-ribose moiety of NADPH.
The flipping of the trimethoxybenzyl group of TMP has already
been extensively studied for the L. casei enzyme. In this organ-
ism the presence of the NADPH decreases by 70-fold the rate
of flipping of the trimethoxybenzyl group of TMP (Searle et al.,
1988; Polshakov et al., 1999). The flipping of rings cannot be
considered independent of the protein structure. Indeed, a relax-
ation of the DHFR, such as that observed in the open state of the
enzyme, is required to allow this. However, when the ribose-
nicotinamide moiety from NADPH is engaged in the active site,
the flipping of TMP should decrease considerably, with the tri-
methoxybenzyl group held in a more restricted conformation,
probably as defined by Li et al. (2000).s reserved
Figure 5. Binding of the TMP to the Open
and Closed Conformation of MtDHFR
(A) Open structure ofMtDHFR in a ternary complex
with NADPH and TMP. The NADPH and TMP are
shown with electron density contoured to 1.0
sigma.
(B) Superposition of the closed (blue) and open
(green) states of MtDHFR in ternary complex with
NADPH and TMP with a zoom in the binding site.
(C) The structure of TMP, showing the 2 of
conformational freedom (q1 and q2).
(D) Conformational changes of the residues of the
active site of the TMP binding site in open (green)
and closed (blue) MtDHFR in ternary complex with
NADPH and TMP.
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Mycobacterium Tuberculosis DHFR StructuresThe Binding of PYR and CYC to the Open Conformation
of MtDHFR
PYR and CYC are molecules that have a pyrimidine and a
triazine ring, with a chlorophenyl ring attached directly to N1
or N6, respectively. Unlike TMP, these molecules are rigid and
the chlorophenyl group can only rotate around its own axis.
Structures of the MtDHFR in ternary complex with NADPH
and PYR or CYC reveal that the pyrimidine and triazine rings
sit in the same positions as observed in the ternary complex
with TMP (Figure 6). The pyrimidine ring of PYR makes a
hydrogen bond interaction with the side chain of Asp27 and
the carbonyl oxygen of the main chain of Ile5 and Ile94. There
is also an interaction mediated by a water molecule with the
side chains of His30 and Thr113 and the main chain carbonyl
of Glu111 and Trp6 and the main chain N of Thr113 (Figure 6C).
The pyrimidine ring makes a stacking p interaction with Phe31
(Figure 6C). However, the chlorophenyl group makes only a
van der Waals interaction with the side chain of Phe31, Leu50,
and Ile94 (Figure 6C).
The most significant difference observed between the struc-
tures of MtDHFR:NADPH:PYR and MtDHFR:NADPH:CYC is in
the side chain of Gln28 that moves away from the active site.
This movement is caused by 6-ethyl group of PYR that is longer
than the 6,6 dimethyl group of triazine group of CYC and conse-
quently causes a repulsion of the Gln28 side chain (Figure 6C).
Comparison between MtDHFR:NADPH:PYR, PvDHFR:
NADPH:PYR (plasmodium vivax DHFR) (Kongsaeree et al.,
2005), and the closed MtDHFR:NADPH supports the hypothesis
that the chlorophenyl of PYR can rotate by 40 around the bond
that connects the two aromatic rings, in order to optimize a p
interaction with the nicotinamide moiety of NADPH. The move-
ment of the helix aB on formation of the closed state allows
the chloride atom to establish an interaction with Ser49. On the
other hand, the structure of Trypanosoma cruzi DHFR-thymidy-
late synthase in complex with CY C (Protein Data Bank [PDB]
code 3IRM) shows a smaller rotation of chlorophenyl ring and
does not allow the formation of the interaction with the corre-
sponding serine of its active site. However, to establish whetherStructure 22, 94–103, January 7, 201there is an interaction between the Ser49
and these inhibitors, the crystallographic
structure of MtDHFR in complex with
PYR or CYC in a closed state is neces-
sary. However, attempts to obtain crystalstructures for these complexes only gave crystals in open
conformation where this interaction is not observed.
The Flipping of the Nicotinamide Moiety and the Weak
Inhibition of TMP and Other Antifolate Drugs
Several studies have demonstrated thatM. tuberculosis is resis-
tant to TMP, which has little or no effect on the growth at subin-
hibitory concentrations. However,M. tuberculosis is susceptible
to sulfamethoxazole that inhibits the enzyme 7,8-dihydropter-
oate synthase (DHPS) (Vilche`ze and Jacobs, 2012, Huang
et al., 2012) and it is highly susceptible to methotrexate, confirm-
ing that the MtDHFR is essential for the survival (Vilche`ze and
Jacobs, 2012).
The structures described here suggest that Tyr100 in MtDHFR
may contribute for the weak binding of TMP, and possibly also of
PYR and CYC, by sterically interfering with the nicotinamide
group of NADPH and consequently decreasing the affinity for
antifolate drugs. In order to gain further evidence for this idea,
we constructed the mutant Y100F and compared its affinity for
TMP, PYR, and CYC with those of the wild-type by isothermal
titration calorimetry (Figure S2). The Kd of TMP for the wild-type
enzyme is 1.43 mMcompared to 0.82 mM for themutant, whereas
the Kd values of PYR andCYC forMtDHFR are 0.91 and 1.26 mM,
respectively, compared to 0.24 and 0.23 mM of the mutant,
demonstrating an increase in affinity of more than 1.5 times for
TMP and 4–5 times for PYR and CYC (Table 2). Although the
change of affinity is small, it shows that the side chain hydroxyl
group of Tyr100 has an effect on the binding of the TMP and
evenmore so on the smaller compounds, PYR andCYC. In these
most of the interactions are made by the pyrimidine ring that
makes a p interaction with the nicotinamide ring of NADPH.
These results suggest that the gain of affinity by the mutant
Y100F might be obtained by increasing the ordering of the
ribose-nicotinamide moiety in the active site, leading to stronger
p-interaction with the pyrimidine rings of the TMP and PYR and
the triazine ring of CYC. Resistance to TMP in Staphylococcus
aureus can result from the replacement of Phe98 by a tyro-
sine, which causes the NADPH to adopt a new alternative4 ª2014 Elsevier Ltd All rights reserved 99
Figure 6. MtDHFR in Complex with PYR and CYC
(A) Crystal structure for the ternary complex of MtDHFR:NADPH:PYR with electronic density for the ligands contoured to 1.0 sigma.
(B) MtDHFR:NADPH:CYC with electronic density for the ligands contoured to 1.0 sigma.
(C) Binding site and comparison of the binding of PYR and CYC. The residues in green and pink are from MtDHFR:NADPH:PYR and MtDHFR:NADPH:CYC,
respectively. Themolecules in yellow and orange are PYR and CYC, respectively, and the black lines represent the hydrogen bond interactions between the PYR
and MtDHFR (the network of hydrogen bonds also is conserved in the complex MtDHFR:NADPH:Cyc).
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Mycobacterium Tuberculosis DHFR Structuresconformation and decreases the number of hydrophobic inter-
actions with DHFR inhibitors. Frey et al. (2009) have observed
that, in the crystal structures of the mutant F98Y in complex
with NADPH and TMP as well as a series of propargyl-like
DHFR inhibitors, this alternative conformation of the NADPH
may be involved in resistance to TMP. In the structures of
SaDHFR, the pyrophosphate of NADPH is rotated, leading to a
reorientation of the ribose and nicotinamide moieties. This prob-
ably results from a steric interaction between the Tyr98 hydroxyl
group and the nicotinamide ring of NADPH, which decreases the
hydrophobic interactions with Phe92 and with the ligands.
In the closed state of MtDHFR, Tyr100 is near to the nicotin-
amide group, playing a role equivalent to that of Phe98 in
SaDHFR. Tyr100 may also interact with the nicotinamide moiety
of NADPH making the pyrophosphate group rotate and flipping
the ribose-nicotinamide moiety out of the active site; lacking
interaction with the protein, this becomes flexible and conse-
quently is not observed in the electron density maps (Figure 7).
However, as the p interaction between the nicotinamide group
of NADPHand the pyrimidine ring of TMP is essential, the nicotin-
amide group may adopt a new conformation flipping the pyrimi-
dine moiety and consequently decreasing its affinity. Analysis
of the ITC results shows that the relative enthalpic contribution
to affinity for TMP differs considerably for wild-type enzyme
(DH of 2.97 kcal mol1) and mutant Y100F (DH of 6.13 kcal
mol1), indicating that the binding mode of TMPmay be different
(Holdgate and Ward, 2005). On other hand, for PYR and CYC
rigid compounds, the relative enthalpic contribution differs only
slightly between the wild-type (DH of 3.55 and 2.31 kcal
mol1 for PYR and CYC, respectively) and the mutant enzyme
(DH of 4.05 and 3.29 kcal mol1), indicating that these com-
pounds bind in the same mode. Unfortunately, we were unable
to obtain crystals of sufficient quality of the mutant Y100F in
binary complex with NADPH or in ternary complex with classical
DHFR inhibitors in order to test this hypothesis.
EXPERIMENTAL PROCEDURES
Cloning, Expression, and Purification
The dfrA gene fromM. tuberculosis (H37Rv) was amplified from genomic DNA
through PCR using the following primers: 50-CGCCATATGGTGGGGCTG100 Structure 22, 94–103, January 7, 2014 ª2014 Elsevier Ltd All righATCTGGGCTCAAGCG-30 and 50-CGCAAGCTTTCATGAGCGGTGGTAGCTG
TACAACCG-30 with restriction sites for the enzymes NdeI and HindIII shown in
bold, respectively. The dfrA PCR product was digested with the restriction
enzymes described above and inserted into a pET28a(+) vector (Novagen)
that had also been previously treated with same restriction enzyme for linear-
izing. pET28a(+) carrying the dfrA gene (pET28a(+):dfrA) was transformed in
BL21(DE3) competent cells and expressed and purified following the protocol
established by Argyrou et al. (2006) with modifications. Briefly the BL21 (DE3)
carrying the pET28a(+):dfrA plasmid was grown until an OD600 = 0.5–0.7 at
37C and an induced with 0.2–1.0 mM IPTG for 20 hr at 20C. The cells
were harvested using 20 mM triethanolamine (TEA), 50 mM KCl, pH 7.8
(buffer A), and disrupted using the Emulsiflex (Avestin) or French Press with
the addition of a tablet of complete protease inhibitor (Roche) and 1mMDNase
(Sigma). The soluble and insoluble fractions were separated by centrifugation
for 1 hr at 10,000 rpm and the supernatant applied to a 5 ml immobilized metal
ion affinity chromatography (IMAC) column (GE Healthcare) charged with
nickel. The column was washed with 50 ml of buffer A and eluted with a linear
gradient of buffer B (20mM TEA, 50mMKCl, 500mM imidazole, pH 7.8). Frac-
tions containingMtDHFRwere collected, concentrated down, and applied to a
Superdex 200/60 column (GEHealthcare) previously equilibrated with buffer A.
The protein was eluted using Buffer C (20 mM potassium phosphate, 50 mM
KCl, pH 7.0), concentrated down to 20 mg/ml and stored at 80C.
Site-Directed Mutagenesis
The wild-type pET28a(+):dfrA plasmid was used as a template to construct the
pET28a(+) carrying the Y100F dfrAmutant gene. To construct this mutant, we
designed sense (CGGAGGCGGACAAGTCTTTGCGCTGGC) and antisense
(GCCAGCGCAAAGACTTGTCCGCCTCCG) primers. We submitted these
primers to a PCR reaction using Phusion DNA polymerase (New England
BioLabs) using the manufacturing instructions. However, we increased the
annealing time to 5 min. The product of reaction was digested by DpnI and
transformed in DH5a competent cells. Single colonies were isolated, the
plasmid was extracted and the presence of the mutation was verified by
sequencing of the dfrA gene.
Isothermal Titration Calorimetry
Isothermal titration calorimetry (ITC) experiments were carried on a VP-ITC
isothermal calorimeter from MicroCal at 299 K. Both cell and syringe solutions
were prepared using 95% (v/v) phosphate buffer (20 mM potassium phos-
phate, 50 mM KCl, pH 7.0), 1 mM NADPH, and 5% (v/v) DMSO. In addition,
the cell solution contained 40 mM MtDHFR or mutant Y100F. The concentra-
tion of ligand (trimethoprim, pyrimethamine, or cycloguanil) in the syringe
was 700 mM. We used 25 injections, the first of 3 ml and other 24 of 10 ml,
with an interval of 300 s and a stirring speed of 300 rpm. For each ITC exper-
iment, the obtained curve was fitted by nonlinear least-squares regression
using the noninteraction one-site model in Origen v. 7.0 (MicroCal).ts reserved
Figure 7. Possible Steric Effect of the Tyr100 on the Nicotinamide
Group of the NADPH Based on the Structure of SaDHFR
The alternative conformation of the SaDHFR (in white), the closed state of
MtDHFR with the full length of NADPH (in purple), and in green the open state
of MtDHFR with truncated NADPH (in green).
Table 2. Thermodynamic Parameters of Trimethoprim,
Pyrimethamine, and Cycloguanil Binding to MtDHFR or Y100F
Mutant
Ligand Kd (mM) DG( Kcal Mol
1) DH (Kcal Mol1)
TDS
(Kcal Mol1)
MtDHFR
TMP 1.43 9.67 2.97 6.70
PYR 0.91 8.27 3.55 4.72
CYC 1.26 8.07 2.31 5.77
Y100F
TMP 0.82 8.32 6.13 2.19
PYR 0.24 9.07 4.05 5.02
CYC 0.23 9.09 3.29 5.80
CYC, cycloguanil; ITC, isothermal titration calorimetry; PYR, pyrimeth-
amine; TMP, trimethoprim.
The fitted curves of the ITC results are shown in Figure S2.
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An aliquot (4.5 ml containing 4.0 mg) of the protein or NADPH was injected by
C18 (100 mm 3 100 mm) RP-UPLC (nanoAcquity UPLC, Waters) coupled
with nano-electrospray tandem mass spectrometry on a Q-Tof Premier
mass spectrometer (Waters) at a flow rate of 600 nl/min. The gradient was
0%–50% acetonitrile in 0.1% formic acid over 45 min. The instrument was
operated in MS continuum mode and the data acquisition was from m/z
100–3,000 at a scan rate of 1 s and an interscan delay of 0.1 s. The spectra
were accumulated about 100 scans and the multiple charged data produced
by the mass spectrometer on the m/z scale were converted to the mass
(molecular weight) scale using Maximum Entropy-based software (Ferrige
et al., 1992) supplied with Masslynx 4.1 software package. The processing
parameters were: output mass range 15,000–25,000 Da at a ‘‘resolution’’ of
0.1 Da/channel; the simulated isotope pattern model was used with the spec-
trum blur width parameter set to 0.2 Da, the minimum intensity ratios between
successive peaks were 20% (left and right). The deconvoluted spectrum was
then smoothed (23 4 channels, Savitzky Golay smooth) and themass centroid
values obtained using 80% of the peak top and a minimum peak width at half
height of four channels.
Crystallization of MtDHFR
Crystallization trials with MtDHFR at a concentration of 10 mg/ml in presence
of 10 mM NADPH in buffer C were carried out using a Cartesian HONEYBEE
crystallization robot (Genomic solutions). The binary complex of MtDHFR:
NADPH was screened using the Classics, Peg I, and Peg II (QIAGEN) crystal-
lization kits. One hundred microliters of the crystallization solution were added
to the reservoirs of the 96-well plate for sitting-drop vapor diffusion (Molecular
Dimensions). The drop had a volume of 100 nl and a ratio of 1:1 of protein and
reservoir solution. Crystals appeared in several conditions between a few days
andweeks. Crystals for MtDHFR appeared in conditions based on PEGs (2000
MME, 4000 MME, and 6000 MME) and with different buffers and pHs (4.6–7)
which are summarized in the Table 1.
Even in thebest conditions for reproducing the crystals, described in Table 1,
the crystals were generally formed as clusters. Cocrystallization and soaking
experiments with different inhibitors were performed. For cocrystallization
the MtDHFR:NADPH was incubated in the presence of 2–5 mM compounds.
Cocrystals could be reproduced in the same condition as for the binary com-
plex of MtDHFR:NADPH. For soaking, 0.1 ml of a solution of 50 mM of com-
pound was added to the drop with mother solution and a crystal of the binary
complex of MtDHFR:NADPH.
Data Collection and Structure Determination
X-ray data were collected at the European Synchrotron Radiation Facility
(ESRF), France and Swiss Light Source (SLS). The data sets were processed
using the program iMosflm (Battye et al., 2011) and scaled by Scala (Evans,
2006) from the CCP4 suite 6.2.0 (Potterton et al., 2003). The structures were
solved by molecular replacement using the program Phaser (McCoy, 2007)Structure 22, 9with the binary complex of MtDHFR:NADPH previously deposited in the
PDB (1DG8) as a probe (Li et al., 2000). The refinement was carried out using
the program REFMAC 5.6.0117. (Murshudov et al., 1997) or PHENIX version
1.7.3-928 (Adams et al., 2010); visual inspection and addition of water were
performed using Coot (Emsley and Cowtan, 2004). The program PyMOL
(The PyMOL Molecular Graphics System, Version 1.5.x Schro¨dinger) and
Coot were used for generation of high quality figures, for analysis, and for
comparison of structures.
Conclusions
The structures of MtDHFR complexes, together with the results of isothermal
titration calorimetry and mass spectrometry, demonstrate that MtDHFR has
two conformational states that differ in the flexibility of the nicotinamide-ribose
moiety of NADPH. Interactions with this moiety lead to a closed, and catalyti-
cally active state. However, the flexibility of the nicotinamide-ribose moiety
interferes with the binding of the clinically important inhibitors, trimethoprim,
pyrimethamine and cycloguanil, due to the loss of a p-interaction. The flipping
of thenicotinamide-ribosemoiety in andout of the active site is increasedby the
hydroxyphenyl side chain of Tyr100 that causes steric interference with
the nicotinamide groupand leads to the loss of thep interactionwith these anti-
folate drugs. Replacement of the equivalent phenylalanine for a tyrosine in
S. aureus causes resistance to trimethoprim due to the adoption of an alterna-
tive conformation by NADPH. As MtDHFR has a tyrosine in the same position
and the affinity by trimethoprim, pyrimethamine or cycloguanil increases
when the Tyr100 is mutated for a phenylalanine, we argue that MtDHFR may
be only weakly inhibited by these antifolate drugs, and this is likely one of the
reasonsof trimethoprimhas lowor noactivity againstM. tuberculosis. Attempts
to obtain the crystal structures of the complexes of MtDHFR with NADPH
and pyrimethamine and cycloguanil in a closed state were unsuccessful.
In the light of these observations, the design of molecules that interact with
the enzyme independently of the NADPH could allow the discovery of stronger
inhibitors for MtDHFR that overcome the dynamic effect of the NADPH and
therefore have better inhibitory proprieties.
ACCESSION NUMBERS
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4KM2. The PDB accession number for the the MtDHFR:NADPH:Pyr reported
in this paper is 4KM0. The PDB accession number for the the closed
NtDHFR:NADPH:Cyc reported in this paper is 4KNE.
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